These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36089530)

  • 1. Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
    Kavoussi M; Nasrallah AA; Williams SB
    Eur Urol; 2022 Dec; 82(6):659. PubMed ID: 36089530
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
    J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
    Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
    J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
    Bukavina L; Bell S; Packiam VT; Smaldone M; Abbosh P; Uzzo R; Kutikov A; Correa AF; Magee DE
    Urol Oncol; 2023 Sep; 41(9):391.e1-391.e4. PubMed ID: 37127478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
    Meeks JJ; Sexton WJ; Clark PE
    J Urol; 2022 Sep; 208(3):526-527. PubMed ID: 35549526
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
    Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
    Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
    Patel SH; Gabrielson AT; Chan S; Schwartz D; Collins C; Singla N; Trock B; Bivalacqua TJ; Hahn N; Kates MR
    J Urol; 2024 Jul; 212(1):95-103. PubMed ID: 38653234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer.
    McElree IM; Orzel J; Stubbee R; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
    Urol Oncol; 2023 Dec; 41(12):485.e1-485.e7. PubMed ID: 37442741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
    Kawada T; Yanagisawa T; Araki M; Pradere B; Shariat SF
    Curr Opin Urol; 2023 May; 33(3):211-218. PubMed ID: 36482766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
    Roumiguié M; Black PC
    Eur Urol Focus; 2022 Jul; 8(4):1117-1120. PubMed ID: 34593355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
    Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M
    Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now.
    Steinberg RL; O'Donnell MA; Packiam VT
    J Urol; 2023 Jul; 210(1):5-7. PubMed ID: 37000006
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
    McElree IM; Packiam VT; Steinberg RL; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA
    J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan WS; Grajales V; Bree K; Li R; Nogueras-Gonzalez GM; Navai N; Dinney C; Kamat AM
    BJU Int; 2023 Oct; 132(4):384-386. PubMed ID: 37246493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.